Literature DB >> 2012258

Experimental Onchocerca volvulus infections in mangabey monkeys (Cercocebus atys) compared to infections in humans and chimpanzees (Pan troglodytes).

M L Eberhard1, J W Dickerson, A E Boyer, V C Tsang, R Zea-Flores, E M Walker, F O Richards, G Zea-Flores, E Strobert.   

Abstract

Three chimpanzees, three mangabey monkeys (Cercocebus atys), and 14 patas monkeys (Erythrocebus patas) were inoculated with L3 Onchocerca volvulus of Guatemalan origin. One chimpanzee and two mangabey monkeys developed antibody activity to at least three different antigens. Both mangabey monkeys recognized a 20 kDa antigen 3.5-5 months post-inoculation, and the monkeys and the chimpanzee developed antibody activity to 14 and 22 kDa antigens 7.5-13 months post-inoculation. One mangabey monkey and the chimpanzee became microfilaria-positive in skin snips at 16 and 21 months post-inoculation, respectively. Antibody activity to the 20 kDa antigen in the mangabey monkeys is noteworthy because of the prominence of this antigen among putatively immune persons living in onchocerciasis-endemic areas. The two mangabey monkeys responded parasitologically in a manner comparable to immune humans. No microfilariae were detected in one monkey and only scant numbers of microfilariae were observed in the second. The mangabey monkey may be a good animal model for the study of onchocerciasis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2012258     DOI: 10.4269/ajtmh.1991.44.151

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  8 in total

1.  Evaluation of an OV-16 IgG4 Enzyme-Linked Immunosorbent Assay in Humans and Its Application to Determine the Dynamics of Antibody Responses in a Non-Human Primate Model of Onchocerca volvulus Infection.

Authors:  Vitaliano A Cama; Circe McDonald; Alice Arcury-Quandt; Mark Eberhard; M Harley Jenks; Jared Smith; Sindew M Feleke; Francisca Abanyie; Lakwo Thomson; Ryan E Wiegand; Paul T Cantey
Journal:  Am J Trop Med Hyg       Date:  2018-10       Impact factor: 2.345

2.  Population biology of human onchocerciasis.

Authors:  M G Basáñez; M Boussinesq
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-04-29       Impact factor: 6.237

3.  Preliminary evaluation of recombinant Onchocerca volvulus antigens for serodiagnosis of onchocerciasis.

Authors:  A F Ogunrinade; R Chandrashekar; M L Eberhard; G J Weil
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

4.  Integrating Multiple Biomarkers to Increase Sensitivity for the Detection of Onchocerca volvulus Infection.

Authors:  Sasisekhar Bennuru; Georgiette Oduro-Boateng; Chinweoke Osigwe; Priscilla Del Valle; Allison Golden; Guilherme Maerschner Ogawa; Vitaliano Cama; Sara Lustigman; Thomas B Nutman
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 7.759

5.  Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis.

Authors:  Christina A Bulman; Chelsea M Bidlow; Sara Lustigman; Fidelis Cho-Ngwa; David Williams; Alberto A Rascón; Nancy Tricoche; Moses Samje; Aaron Bell; Brian Suzuki; K C Lim; Nonglak Supakorndej; Prasit Supakorndej; Alan R Wolfe; Giselle M Knudsen; Steven Chen; Chris Wilson; Kean-Hooi Ang; Michelle Arkin; Jiri Gut; Chris Franklin; Chris Marcellino; James H McKerrow; Anjan Debnath; Judy A Sakanari
Journal:  PLoS Negl Trop Dis       Date:  2015-02-20

6.  Development of Onchocerca volvulus in humanized NSG mice and detection of parasite biomarkers in urine and serum.

Authors:  John B Patton; Sasisekhar Bennuru; Mark L Eberhard; Jessica A Hess; April Torigian; Sara Lustigman; Thomas B Nutman; David Abraham
Journal:  PLoS Negl Trop Dis       Date:  2018-12-12

Review 7.  Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With Onchocerca ochengi.

Authors:  Bin Zhan; Maria Elena Bottazzi; Peter J Hotez; Sara Lustigman
Journal:  Front Cell Infect Microbiol       Date:  2022-04-04       Impact factor: 6.073

8.  Individuals living in an onchocerciasis focus and treated three-monthly with ivermectin develop fewer new onchocercal nodules than individuals treated annually.

Authors:  Jérémy T Campillo; Cédric B Chesnais; Sébastien D S Pion; Jacques Gardon; Joseph Kamgno; Michel Boussinesq
Journal:  Parasit Vectors       Date:  2020-05-15       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.